A
Adyb Baakili
Researcher at Bristol-Myers Squibb
Publications - 9
Citations - 184
Adyb Baakili is an academic researcher from Bristol-Myers Squibb. The author has contributed to research in topics: Nivolumab & Sorafenib. The author has an hindex of 7, co-authored 9 publications receiving 150 citations.
Papers
More filters
Journal ArticleDOI
Nivolumab (nivo) in sorafenib (sor)-naive and -experienced pts with advanced hepatocellular carcinoma (HCC): CheckMate 040 study.
Todd S. Crocenzi,Anthony B. El-Khoueiry,Thomas Yau,Ignacio Melero,Bruno Sangro,Masatoshi Kudo,Chiun Hsu,Jörg Trojan,Tae-You Kim,Su Pin Choo,Tim Meyer,Yoon-Koo Kang,Winnie Yeo,Akhil Chopra,Adyb Baakili,Christine Dela Cruz,Lixin Lang,Jaclyn Neely,Theodore H. Welling +18 more
TL;DR: Nivo is a fully human anti–PD-1 IgG4 mAb that demonstrated durable responses in patients with advanced HCC on SOC therapy and was approved by the European Medicines Agency (EMA) as well as the US Food and Drug Administration (FDA) for similar reasons.
Journal ArticleDOI
Impact of antitumor activity on survival outcomes, and nonconventional benefit, with nivolumab (NIVO) in patients with advanced hepatocellular carcinoma (aHCC): Subanalyses of CheckMate-040.
Anthony B. El-Khoueiry,Ignacio Melero,Thomas Yau,Todd S. Crocenzi,Masatoshi Kudo,Chiun Hsu,Su Pin Choo,Jörg Trojan,Theodore H. Welling,Tim Meyer,Yoon-Koo Kang,Winnie Yeo,Akhil Chopra,Huanyu Zhao,Adyb Baakili,Christine Dela Cruz,Bruno Sangro +16 more
TL;DR: NIVO (anti–PD-1 mAb) has demonstrated durable responses, long-term OS, and manageable safety in pts with aHCC in CheckMate-040 and with anti–PD–1 thera...
Journal ArticleDOI
Brief Report: Switch to Ritonavir-Boosted Atazanavir Plus Raltegravir in Virologically Suppressed Patients With HIV-1 Infection: A Randomized Pilot Study.
Jan van Lunzen,Anton Pozniak,José M. Gatell,Andrea Antinori,Isabelle Klauck,Oscar Serrano,Adyb Baakili,Olayemi Osiyemi,Heather Sevinsky,Pierre Marie Girard +9 more
TL;DR: In this article, the authors randomized adults with HIV-1 RNA <40 copies per milliliter and nucleos(t)ide-related safety/tolerability issues to switch to ritonavir-boosted atazanavir (ATV/r) plus tenofovir disoproxil fumarate/emtricitabine (n = 37).
Nivolumab in Sorafenib-Naive and -Experienced Patients With Advanced Hepatocellular Carcinoma (HCC): Survival, Hepatic Safety, and Biomarker Assessments in CheckMate 040
Bruno Sangro,Ignacio Melero,Thomas Yau,C.-H. Hsu,Masatoshi Kudo,T-Y Kim,S.P. Choo,Joerg Trojan,Theodore H. Welling,Tim Meyer,Y-K Kang,Winnie Yeo,Akhil Chopra,Adyb Baakili,C dela Cruz,Hongyu Zhao,Jaclyn Neely,Todd S. Crocenzi,Anthony B. El-Khoueiry +18 more
Nivolumab in sorafenib-naive and - experienced patients with advanced hepatocellular carcinoma (HCC): checkMate 040 study
Joerg Trojan,Todd S. Crocenzi,Anthony B. El-Khoueiry,Thomas Yau,Ignacio Melero,Bruno Sangro,Masatoshi Kudo,C.-H. Hsu,T-Y Kim,S.P. Choo,Tim Meyer,Y-K Kang,Winnie Yeo,Akhil Chopra,Adyb Baakili,C dela Cruz,Lixin Lang,Jaclyn Neely,Theodore H. Welling +18 more